Quipt Home Medical (QIPT) - 2021 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Quipt Home Medical reported revenue of $26.2 million in Q3 2021, a 41% increase from Q3 2020 [14] - Adjusted EBITDA for Q3 2021 was $5.3 million, up 21% year-over-year [15] - Bad debt expense improved to 8% for the nine months ending June 2021, down from 10% in the same period in 2020 [11][14] - Cash flow from operations for the nine months ending June 2021 was $11.9 million, compared to $9.8 million in the corresponding period in 2020 [16] Business Line Data and Key Metrics Changes - Quipt completed 95,192 setups in Q3 2021, a 65% increase from 57,551 setups in Q3 2020 [13] - Respiratory resupply setups increased by 181%, from 14,436 in Q3 2020 to 40,580 in Q3 2021 [13] - The customer base grew by 74% year-over-year, reaching 64,578 unique patients served in Q3 2021 [13] Market Data and Key Metrics Changes - Quipt operates in 60 locations across 15 states, with a focus on the Midwest, Southeast, and East Coast regions [6] - The company has seen strong demand for ventilators, sleep, and oxygen equipment, contributing to sustained growth across all product lines [16] Company Strategy and Development Direction - Quipt aims to become a national leader in respiratory care, focusing on organic growth, technology implementation, and accretive acquisitions [6][20] - The company is expanding its geographical footprint and has entered five new states since mid-July 2021 [20] - Quipt's growth strategy includes capturing market share, leading in technology deployment, and pursuing acquisitions of turnkey respiratory operations [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory environment, noting the cancellation of the 2021 competitive bidding program as a significant tailwind [10][48] - The company anticipates continued growth in Q4 2021 and beyond, supported by a robust M&A pipeline and strong operational performance [17][18] - Management highlighted the importance of home care and the ongoing shift towards treating patients in home settings as a key industry trend [21][22] Other Important Information - Quipt has approximately $33 million in cash on hand and an undrawn $20 million credit facility, providing financial flexibility for acquisitions [18] - The company has hired David Chester to lead its M&A and integration team, enhancing its acquisition strategy [18] Q&A Session Summary Question: Confirmation of EBITDA including NASDAQ transaction costs - Management confirmed that the reported EBITDA of $5.3 million includes approximately $400,000 in NASDAQ listing costs, suggesting adjusted earnings closer to $5.7 million [30][31] Question: Organic growth quarter-over-quarter - Management indicated that quarter-over-quarter growth was in the range of 4% to 5%, aligning with expectations of continued outperformance against industry averages [32][33] Question: Revenue per patient analysis - Management stated that revenue per patient is not a reliable metric due to various underlying variables, making it difficult to predict future trends [35][36] Question: Impact of cash flow increase - The increase in cash was attributed to a combination of cash flow from operations, warrant exercises, and net effects from recent acquisitions [37] Question: Geographic expansion strategy - Management plans to expand into new states with high COPD patient acuity, focusing on integrating acquired businesses into existing hubs [40] Question: COVID-19 impact on patient referrals - Management noted an uptick in home oxygen demand but did not see significant changes in patient referrals due to COVID-19 [42] Question: M&A pipeline characterization - Management described a robust M&A pipeline with numerous opportunities, emphasizing a methodical approach to capital deployment [44][45] Question: Changes in funding and reimbursement environment - Management expressed confidence in the current regulatory and reimbursement environment, highlighting opportunities for national contracts with payers [48][50] Question: Bad debt expense sustainability - Management indicated that maintaining bad debt expense between 8% to 10% is a comfortable range, with ongoing integration of acquired assets potentially affecting this metric [59][60]